Washington — Federal health officials posted a warning Tuesday about misleading statements made by biotech billionaire Dr. Patrick Soon-Shiong, who recently told podcast listeners his company's ...

Oncuria-Detect and EarlyTect BCD Plus assays may promote earlier detection of bladder cancer following hematuria. When hematuria is emergent, prompt investigation and diagnosis can be lifesaving. The ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

The US Supreme Court cleared the way for a multibillion-dollar racketeering lawsuit that accuses Takeda Pharmaceutical Co. and Eli Lilly & Co. of marketing the Actos diabetes drug without disclosing ...

MHN has signed support of 2 policies: a Bladder Cancer Research Program within DoD & recognition of post-baccalaureate nursing degrees as professional degrees. Expanding the workforce of nurses & ...

After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his story to life in his first commercial for the company. Sanders starred in ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...

Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the ...

A binary dual-stain immunohistochemistry classifier to predict pathologic downstaging after neoadjuvant chemotherapy in muscle-invasive bladder cancer. This is an ASCO Meeting Abstract from the 2026 ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients as “impressive,” despite this rate halving at the 12-month mark. The New ...

Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may ...